Singapore, Jan. 12 -- Japanese pharmaceutical firm Takeda has announced a global collaboration and license agreement with US-based Halozyme Therapeutics, Inc., granting Takeda exclusive access to Halozyme's innovative ENHANZE(R) drug delivery technology for use with vedolizumab.

This partnership underscores Takeda's commitment to advancing patient care and unlocking new possibilities for vedolizumab, which is marketed under the trade name ENTYVIO(R). Entyvio is approved for the treatment of adult patients with moderately to severely active ulcerative colitis and Crohn's disease.

Ulcerative colitis and Crohn's disease, the two most prevalent forms of inflammatory bowel disease (IBD), are chronic, complex, and unpredictable conditions. Ea...